Skip to Content

Kitov Pharma Ltd ADR KTOV

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Kitov Pharma Ltd is a development stage biopharmaceutical company. It focuses on the development of KIT-302, a combination drug for the simultaneous treatment of two clinical conditions pain caused by osteoarthritis and hypertension; and NT219 which is a fixed-dose combination of two drug products that treat osteoarthritis pain and hypertension simultaneously. The company's operating segment include Pain and Hypertension and Oncology, It generates maximum revenue from the Pain and Hypertension segment.

Contact
132 Menachem Begin Road, One Azrieli Center, Round Tower, Floor 19
Tel Aviv, 6701101, Israel
T +972 39333121
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2015
Fiscal Year End Dec 31, 2020
Stock Type
Employees 9